Rezolute
Yahoo Finance • 10 days ago
Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today reported financial... Full story
Yahoo Finance • 19 days ago
Rezolute Hits 52-Week High On Ersodetug Progress In UpLIFT And SunRIZE Trials For Hyperinsulinism
(RTTNews) - Shares of Rezolute Inc. (RZLT) touched a new 52-week high of $8.06 last week amid FDA alignment on a significantly streamlined clinical development path for its lead asset, Ersodetug, in tumor-induced hyperinsulinism, as well a... Full story
Yahoo Finance • last month
Rezolute to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that manag... Full story
Yahoo Finance • last month
Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer
REDWOOD CITY, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today announced the a... Full story
Yahoo Finance • 2 months ago
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
REDWOOD CITY, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that manag... Full story
Yahoo Finance • 2 months ago
Rezolute posts patient demographics poster for Phase 3 sunRIZE study
Rezolute , Inc. (NASDAQ:RZLT), a $474 million market cap biotech company whose stock has gained over 25% in the past year, announced on Tuesday that it has posted a patient demographic poster related to its ongoing Phase 3 clinical study k... Full story
Yahoo Finance • 2 months ago
Rezolute files to sell 1.3M shares of common stock for holders
* Rezolute (NASDAQ:RZLT [https://seekingalpha.com/symbol/RZLT]) filed to sell 1.3M shares of common stock for holders. * This prospectus is not an offer to sell. * Filing [https://seekingalpha.com/filing/10198821] MORE ON REZOLUTE... Full story
Yahoo Finance • 3 months ago
Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)
REDWOOD CITY, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today announced that... Full story
Yahoo Finance • 3 months ago
Rezolute ticks higher following disclosure of CFO stock buy
[Shares] Bluberries/iStock via Getty Images * Rezolute is up ~5% in Tuesday afternoon trading following the disclosure of a significant purchase of shares from its CFO. * Daron Evans on Tuesday bought [https://seekingalpha.com/filing/... Full story
Yahoo Finance • 3 months ago
Rezolute CFO Evans buys $20,250 in company stock
Rezolute , Inc. (NASDAQ:RZLT) Chief Financial Officer Daron Evans has recently purchased 5,000 shares of the company’s common stock at $4.05 per share, according to a Form 4 filing with the Securities and Exchange Commission. The total val... Full story
Yahoo Finance • 4 months ago
Rezolute, Inc. (RZLT): Analysts See 260% Upside Potential
We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Rezolute, Inc. (NASDAQ:RZLT) was one of the stocks that was covered in that article. Wall Street analysts believe RZLT has a 260% upside potential over th... Full story
Yahoo Finance • 5 months ago
Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today ann... Full story
Yahoo Finance • 6 months ago
Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors
REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, announced the app... Full story
Yahoo Finance • 8 months ago
Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference
REDWOOD CITY, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious u... Full story
Yahoo Finance • 2 years ago
Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day
REDWOOD CITY, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today anno... Full story
Yahoo Finance • 2 years ago
Rezolute Reports First Quarter Fiscal 2024 Results
REDWOOD CITY, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today anno... Full story
Yahoo Finance • 2 years ago
Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism
REDWOOD CITY, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today anno... Full story
Yahoo Finance • 2 years ago
Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism
REDWOOD CITY, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today anno... Full story
Yahoo Finance • 2 years ago
Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress
REDWOOD CITY, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt treatment paradigms for dev... Full story
Yahoo Finance • 2 years ago
Rezolute to Participate in Upcoming Investor Conferences in September
REDWOOD CITY, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms... Full story
